Iohexol clinical trials
Iohexol is named as an intervention in 5 current clinical trials in our USA, Norway, Canada and Israel registers. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Eli Lilly and Company (1). The most-studied condition is Healthy. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Iohexol is approved
All regulators →Of the three regulators tracked here, the first to approve Iohexol was the US, on 26 Dec 1985.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Iohexol
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Iohexol works
All drug targets →- Acute kidney injuryPhase 2
- Type 1 diabetes mellitusPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1200455, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Iohexol
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 8 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Iohexol
- ATC code
- V08AB02
- ChEMBL
- CHEMBL1200455
- DrugBank
- DB01362
- PubChem CID
- 3730
- CAS number
- 66108-95-0
- FDA UNII
- 4419T9MX03
- Wikidata
- Q410683
- Wikipedia
- Iohexol
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Iohexol
5 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of LY4515100 in Healthy Participants
NCT07339722 · Healthy
|
Phase 1 | Recruiting | Eli Lilly and Company | USA |
|
Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
NCT05442463 · ClinicalTrials.gov ↗ · Hormone Therapy
|
Observational | Recruiting | University of Calgary | Canada |
|
Investigations Into Sepsis-associated Acute Kidney Injury
NCT05694624 · ClinicalTrials.gov ↗ · Acute Kidney Injury
|
Observational | Recruiting | University Hospital of North Norway | Norway |
|
MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure
NCT07349797 · Glomerular Filtration Rate, Heart Failure
|
Not applicable | Recruiting | MediBeacon | USA |
|
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NCT03997370 · ClinicalTrials.gov ↗ · Malignant Solid Neoplasm
|
Phase 1 | Active, closed | NRG Oncology | Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Iohexol in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Iohexol. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial
2025-521795-58-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Region Skane | Sweden, Denmark |
Iohexol across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
8 single-substance products containing Iohexol on the HPRA medicines list.
- Omnipaque 180 mg I/ml Solution for Injection (Glass)GE Healthcare AS · PA0735/006/002 · Marketed
- Omnipaque 240 mg I/ml Solution for Injection (Glass)GE Healthcare AS · PA0735/006/004 · Marketed
- Omnipaque 240 mg I/ml Solution for Injection (Polypropylene)GE Healthcare AS · PA0735/006/023 · Marketed
- Omnipaque 300 mg I/ml Solution for Injection (Glass)GE Healthcare AS · PA0735/006/008 · Marketed
- Omnipaque 300 mg I/ml Solution for Injection (Polypropylene)GE Healthcare AS · PA0735/006/018 · Marketed
Supply shortages
- ACCUPAQUE 350Germany (BfArM) · Other reason · 22 May 2026 to 11 Nov 2026
- ACCUPAQUE 350Germany (BfArM) · Other reason · 22 May 2026 to 11 Nov 2026
- ACCUPAQUE 350Germany (BfArM) · Other reason · 22 May 2026 to 11 Nov 2026
- ACCUPAQUE 300Germany (BfArM) · Other reason · 11 Sep 2026 to 11 Nov 2026
Conditions studied with Iohexol
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 1 |
| MediBeacon | 1 |
| University Hospital of North Norway | 1 |
| University of Calgary | 1 |
| NRG Oncology | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in Norway | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Israel | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Iohexol trials
How many clinical trials are testing Iohexol?
5 current trials in our USA, Norway, Canada and Israel registers name Iohexol (also registered as Omnipaque 300) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Iohexol trials recruiting patients?
Yes. 4 of the 5 trials are recruiting: 2 with sites in USA, 1 with sites in Norway and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Iohexol clinical trials?
Eli Lilly and Company (1), MediBeacon (1), University Hospital of North Norway (1) and University of Calgary (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Iohexol licensed in Ireland?
Yes. The HPRA medicines list includes 8 single-substance products containing Iohexol, for example Omnipaque 180 mg I/ml Solution for Injection (Glass) (GE Healthcare AS). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Iohexol shortage?
The registers we track list 4 entries for Iohexol: 4 German notices. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Iohexol works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iohexol works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iohexol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.